Focused On-demand Library for UPF0696 protein C11orf68

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H3H3

UPID:

CK068_HUMAN

Alternative names:

Basophilic leukemia-expressed protein Bles03; Protein p5326

Alternative UPACC:

Q9H3H3; J3KQG9; Q9BT13

Background:

The UPF0696 protein C11orf68, also known as Basophilic leukemia-expressed protein Bles03 and Protein p5326, represents a unique entity in the proteomic landscape. Its nomenclature reflects a diverse potential in biological processes, yet its specific functions and interactions within cellular pathways remain to be fully elucidated. This protein's enigmatic nature sparks curiosity within the scientific community, driving research into its molecular mechanisms.

Therapeutic significance:

Understanding the role of UPF0696 protein C11orf68 could open doors to potential therapeutic strategies. While direct associations with diseases are yet to be established, the protein's unique characteristics suggest its involvement in critical biological processes. This positions it as a potential target for drug discovery, emphasizing the importance of further research to uncover its therapeutic potential.